Delivery Order SPE2DB20D9331-SPE2DB23FL1N9
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $18,107.70 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, which runs through February 2, 2024, is for the supply of the pharmaceutical product BEYFORTUS 100 MG/ML SYRINGEML. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, holding a significant indefinite delivery contract (IDC) with the DLA under the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,711.25 delivery order is for the supply of BEYFORTUS 50 MG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, to support the medical needs of military healthcare facilities. The contract is a firm fixed-price delivery order and is not associated with a set-aside designation. DMS Pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $9,917.34 firm fixed-price delivery order is for BEYFORTUS 100 MG/ML SYRINGEML, a pharmaceutical product, under the DLA's Medical Supply Chain program. The contract does not have a set-aside designation. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA,...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $11,978.75 contract is for the delivery of BEYFORTUS 50 MG/0.5 ML SYRINGE 0.5ML and has a completion date of July 9, 2024. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The $126,753.90 firm fixed-price delivery order is for the supply of BEYFORTUS 100 MG/ML SYRINGEML, a pharmaceutical product. The contract has no set-aside designation. DMS Pharmaceutical Group Inc. holds an Indefinite Delivery Vehicle (IDV) contract, contract 4600082013 under the SPE2DB program, with the DLA valued at up to $4,999,999 through...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide BEYFORTUS 100 MG/ML SYRINGEML. The contract has no set-aside designation, is valued at $22,420.45, and has a completion date of February 28, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that offers a wide range of brand and generic prescription and...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $7,573.50, is for the delivery of the pharmaceutical product BEYFORTUS 50 MG/0.5 ML SYRINGE 0.5ML. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which allows the DLA to issue delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $50,490.00 firm fixed-price contract is for the delivery of BEYFORTUS 50 MG/0.5 ML SYRINGE 0.5ML, with a period of performance through August 28, 2023. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, holding a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
- This federal contract award, valued at $2,975.00, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the pharmaceutical product BEYFORTUS 100 MG/ML SYRINGEML, with a period of performance through September 30, 2024. This contract award is part of a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $9,917.34, is for the supply of the pharmaceutical product BEYFORTUS 100 MG/ML SYRINGEML. The award is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc. under the DLA's SPE2DB program, which has a ceiling value of up to...
- SPE2DB20D9331Indefinite Delivery Contract
- SPE2DB20D9331-SPE2DB23FL1N9Delivery Order
This federal contract award, with the ID SPE2DB20D9331|SPE2DB23FL1N9, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $100,980.00 firm fixed-price delivery order is for the supply of BEYFORTUS 50 MG/0.5 ML SYRINGE 0.5ML, with a period of performance through September 13, 2023. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This single-award IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $101.0k | 9/12/23 |